EPIRUS Biopharmaceuticals (NASDAQ:EPRS) has tumbled 30.62% during the past week and has dropped 26% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 29.78%. EPIRUS Biopharmaceuticals (NASDAQ:EPRS) has underperformed the index by 26.68% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
EPIRUS Biopharmaceuticals (NASDAQ:EPRS): The stock opened at $0.50 on Friday but the bulls could not build on the opening and the stock topped out at $0.50 for the day. The stock traded down to $0.41 during the day, due to lack of any buying support eventually closed down at $0.42 with a loss of -18.37% for the day. The stock had closed at $0.51 on the previous day. The total traded volume was 2,140,989 shares.
The company shares have dropped -93.16% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $8.75 and the one year low was seen on Jun 17, 2016. The 50-Day Moving Average price is $1.09 and the 200 Day Moving Average price is recorded at $2.52.
On the companys insider trading activities, Ticktin Robert, officer (General Counsel) of Epirus Biopharmaceuticals, Inc., executed a transaction worth $11,160 on December 21, 2015. A total of 3,000 shares were purchased at an average price of $3.72. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brokerage Firm, Leerink Swann, downgrades their rating on the shares of EPIRUS Biopharmaceuticals (NASDAQ:EPRS). Leerink Swann has a Market Perform rating on the shares. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 16, 2016. Currently the company Insiders own 13.06% of EPIRUS Biopharmaceuticals shares according to the proxy statements. Institutional Investors own 49.89% of EPIRUS Biopharmaceuticals shares.
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a commercial-stage biopharmaceutical company. The Company is engaged in developing, manufacturing, and commercializing biosimilar therapeutics (biosimilars). The Company has a pipeline of operationally synergistic monoclonal antibodies (MAbs) in inflammation and immunology. The Companys lead product candidate, BOW015 is indicated for the treatment of various inflammatory diseases. The Company has launched BOW015 under the brand name, Infimab. The Companys products include BOW015, which contains infliximab; BOW050, which contains adalimumab; BOW070, which contains tocilizumab; BOW080, which contains eculizumab; BOW090, which contains ustekinumab, and BOW100, which contains golimumab.